Valeant Pharmaceuticals International

  • Extensive Product Portfolio for This Mid-Cap Value Stock

    By Kanak Kanti - August 15, 2013 | Tickers: ACOR, VRX, XNPT

    Acorda Therapeutics (NASDAQ: ACOR) is a mid-cap biotech stock that has created an interesting niche for itself in the neurological disorder market. The company develops walking impairment therapies in multiple sclerosis (MS) patients. It also develops and commercializes other novel therapies for neurological disorders in people with MS, spinal cord injury and other neurological conditions.

    Approved Products

    Ampyra (dalfampridine) is an extended release tablet indicated to improve walking in MS more »

  • 2 Stocks to Buy on Merger Speculation

    By Mohsin Saeed - July 24, 2013 | Tickers: KERX, SLTM, VRX

    Large healthcare companies are facing revenue declines due to expiring patents. These cash rich giants are increasingly investing in small biotechnology companies with promising candidates. Solta Medical (NASDAQ: SLTM) and Keryx Pharmaceuticals (NASDAQ: KERX) are good targets for Big Pharma players looking to diversify or expand patent portfolios.

    Solta’s board is resisting an acquisition but it seems highly likely that activist shareholders will succeed. The shareholders have already rejected more »

  • Brave Warrior Capital’s Top Stock Picks

    By Meena Krishnamsetty - July 15, 2013 | Tickers: SCHW, ESRX, ORCL, VRX, VPRT

    We track quarterly 13F filings from hundreds of hedge funds, including Glenn Greenberg’s Brave Warrior Capital, using the results to help us develop investment strategies (we have found, for example, that the most popular small cap stocks among hedge funds earn an average excess return of 18 percentage points per year).

    The information from individual managers’ filings, even though it is a bit out of date by now (the more »

  • 4 Significant Insider Transactions That You Should Note

    By Brian Nichols - July 1, 2013 | Tickers: GOOG, SMPL, AMTD, VRX

    Courtesy of Insider Insights, I have compiled a list of significant insider/institutional purchases and sales that have been filed with the SEC over the last week--but does this activity indicate that you should buy or sell?

    Before we look at the most significant activity from the last week, keep in mind that most, but not all, took place in the open market. The filer, or person/firm that is more »

  • 3 Pharma Companies to Buy for the Long Run

    By Madhukar Dubey - July 1, 2013 | Tickers: BIIB, ELN, HSP, VRX

    According to IMS health report, the global pharmaceutical industry is expected to grow at a CAGR of 4.5% in the next five years to reach $1.20 trillion in 2017, from $963 billion in 2012. To keep pace with the industry's growth, pharmaceutical companies are spending on research and development in order to develop new drugs, and are pursuing various expansion strategies. These companies are also looking to more »

  • An Insider and His Wife Are Buying This Pharma Stock

    By Meena Krishnamsetty - June 28, 2013 | Tickers: MRK, NVS, REGN, TEVA, VRX

    According to a filing with the SEC, between June 11 and June 12, Valeant Pharmaceuticals (NYSE: VRX) Board member Lloyd Segal directly purchased 2,800 shares of the stock at an average price of $83.85 per share. This gave him a total of slightly more than 21,000 shares of the stock, and came at the same time as his wife purchased close to 400 shares of Valeant.

    We more »

  • Billionaire Julian Robertson’s Top Stock Picks

    By Meena Krishnamsetty - June 27, 2013 | Tickers: GOOG, HRB, HCA, MA, VRX

    We track quarterly 13F filings from hundreds of hedge funds and other notable investors, including legendary investor Julian Robertson (formerly of Tiger Management). We’ve found that the information included in 13Fs can be useful in developing investment strategies (for example, the most popular small cap stocks among hedge funds earn an average excess return of 18 percentage points per year), and of course it can also be useful to more »

  • This Pharmaceutical Stock Promises Robust Returns

    By Kiran Gulati - June 21, 2013 | Tickers: ABT, TEVA, VRX

    The healthcare sector has always been a subject of great interest to investors and analysts alike. With the rise of sedentary lifestyles and increasing stress levels across demographics, the healthcare sector has a huge market to cater to.

    Valeant Pharmaceuticals (NYSE: VRX) is a fast growing company in dermatology, ophthalmology and neurology. Over the years, Valeant has developed a disparate product portfolio comprising of prescription drugs, branded generics and Over more »

  • Warner Chilcott: Should You Buy Joel Greenblatt's Latest Pick?

    By Zarr Pacificador - June 13, 2013 | Tickers: ACT, MYL, VRX, WCRX

    Searching for potential stock investments can be a daunting task. With so many stocks to choose from – more than 2,300 listed on the NYSE and around 2,800 on Nasdaq – how do you find good ideas?

    One way, and the probably the most common way, is the use of stock screens. With information on publicly listed companies increasingly available online, it is easier now to come up with a more »

  • Valeant Biting More Than it Can Chew

    By Kanak Kanti - June 13, 2013 | Tickers: NVS, REGN, VRX

    While the debate goes on whether increasing output by acquiring new businesses through mergers, acquisitions and takeovers is the right way forward, the biopharmaceutical industry continues to be marked by M&A. Valeant Pharmaceuticals (NYSE: VRX) is one such company that is known to swear by the philosophy of aggressive growth-by-acquisition. Last month, the company announced a mega-deal, the biggest acquisition yet by the company at $8.7 billion, to more »

  • Tme to Buy This Defensive Growth Stock?

    By Lee Samaha - June 11, 2013 | Tickers: JNJ, NVO, COO, VRX

    Everyone loves a defensive growth story, and there aren’t many better companies in the category than Cooper Companies (NYSE: COO). In general, ophthalmology is an industry that can grow irrespective of the economy. Within this, Cooper has its own mix of earnings drivers with which it can generate superior industry growth.

    It is a compelling mix. In fact, so much so that the stock has gotten away from this more »

  • This Company is Set for Newer Heights in the Eye-Care Sector

    By Mike Thiessen - June 11, 2013 | Tickers: NVS, TEVA, VRX

    Valeant Pharmaceuticals (NYSE: VRX) has been on an acquisition spree. Its latest purchase is Bausch + Lomb in an all-cash deal worth $8.7 billion. The stock of VRX has been rising over the past year and this takeover will increase it further.

    Involved Parties

    Valeant Pharmaceuticals International is the largest publicly traded Canadian drug maker. Headquartered in Montreal, Quebec, this multinational pharmaceutical company specializes in dermatological and neurological treatments that more »

  • 2 Huge Deals as M&A Accelerates

    By RJ Towner - June 6, 2013 | Tickers: CRM, SFD, VRX

    In one of the more surprising deals in some time, pork producer Smithfield Foods (NYSE: SFD) sold itself to Chinese meat producer Shuanghui International for $4.7 billion, or $34 per share in cash. The price represents a 31% premium to the previous day’s closing price. While American pork consumption languishes, the Chinese have a healthy appetite for the meat. Shuanghui will be able to take excess pork supply more »

  • Valeant Buys Bausch & Lomb, Boosts Cooper Companies and Actavis

    By Jacob Wolinsky - June 3, 2013 | Tickers: ACT, COO, VRX

    Valeant Pharmaceuticals (NYSE: VRX) stirred the merger and acquisition space once again with its announcement that it is about to acquire multinational eye health firm, Bausch & Lomb, for $8.7 billion in cash. Of the total amount, $4.5 billion will be paid to an investor group led by private equity firm Warburg Pincus, while the remaining amount will go toward repaying Bausch & Lomb’s outstanding debt. Valeant Pharmaceuticals has more »

  • Valeant is Expanding its Eye Care Business

    By Anh HOANG - May 30, 2013 | Tickers: AGN, NVS, VRX

    The pharmaceutical industry is getting hotter with increasing M&A activities. Recently, Valeant Pharmaceuticals (NYSE: VRX) agreed to buy out Bausch + Lomb for around $8.7 billion in cash, including $4.2 billion used to pay the target’s debt. Right after the announcement, Valeant jumped more than 13% on the market to nearly $84.50 per share, reaching its all-time high.

    Strategic eye care acquisition

    Bausch + Lomb, the global more »

  • Double Your Money With These 3 Stocks

    By Tanya Kanodia - May 30, 2013 | Tickers: RDN, VRX, ZNGA

    For big companies like Apple and Google, it is unreasonable to expect that your shares will double in value. There are so many analysts covering these companies that they can't help but trade close to a fair price. In contrast, some low-priced stocks remain out of focus, although they have significant upside potential. They are undervalued due to their significant short interest levels or if they are a suitable more »

  • This Acquisition Spree Could Create Future Struggles

    By Brian Nichols - May 28, 2013 | Tickers: VRX, XPO

    Valeant Pharmaceuticals (NYSE: VRX) jumped 8% on Monday, giving the stock a two-day 22% surge. Those large gains stemmed from Valeant's acquisition of Bausch & Lomb for $8.7 billion, which is expected to expand Valeant’s small ophthalmology business.

    According to the Associated Press, adding Bausch & Lomb -- Valeant's 15th purchase since 2010 -- will add $3.3 billion to the company's top line this year.

    Most notably, on more »

  • Sticking With a Winning Strategy

    By Robert Hanley - May 28, 2013 | Tickers: ACT, TEVA, VRX

    Valeant Pharmaceuticals (NYSE: VRX) has built a unique, winning drug business by acquiring underperforming niche product franchises and incorporating them into its efficient operating structure. From 2008 to 2012, the company grew its revenues by 368% through a string of acquisitions, including purchases of Biovail in 2010 and Medicis in 2012. However, Valeant went off strategy last month with its bold attempt to acquire Actavis (NYSE: ACT), the #3 player more »

  • Following Up an Acquisition With an Even Larger Merger?

    By Mike Thiessen - May 15, 2013 | Tickers: ACT, TEVA, VRX

    News that Montreal-based Valeant Pharmaceuticals (NYSE: VRX) was in talks to merge with Parsippany, New Jersey-based Actavis (NYSE: ACT) emerged barely a week after the completion of the company's tender offer for Obagi Pharmaceuticals (OMPI). Although the deal remains in its early stages and has been the subject of wild and conflicting rumors, it could prove to be one of the largest pharmaceutical mergers in recent years. Its current more »

  • Why This Stock's Crash is a Buying Opportunity

    By Lee Samaha - May 13, 2013 | Tickers: AGN, NVO, REGN, VRX

    It’s been a varied reporting season with a general uptrend in markets accompanying more than a few profit warnings. If you’ve been holding some of these names before the disappointments then it has been painful. The good news is that these situations can create buying opportunities. I think Allergan (NYSE: AGN) is a case in point, and here is why.

    Allergan’s Outlook

    It was almost a tale more »

  • Page 1 of 3